tiprankstipranks
Trending News
More News >
Yomeishu Seizo Co., Ltd. (JP:2540)
:2540
Japanese Market

Yomeishu Seizo Co., Ltd. (2540) AI Stock Analysis

Compare
0 Followers

Top Page

JP:2540

Yomeishu Seizo Co., Ltd.

(2540)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 5.2)
Rating:52Neutral
Price Target:
¥4,091.00
▼(-14.77% Downside)
Action:ReiteratedDate:02/26/26
The score is held up by an exceptionally conservative, debt-free balance sheet, but is reduced by weakening profitability and materially negative free cash flow. Technical indicators also point to near-term downside momentum, and valuation looks demanding given the very high P/E and only modest dividend yield.
Positive Factors
Debt-free balance sheet
Zero debt and a large equity base provide durable financial flexibility, lowering insolvency risk and enabling the company to fund operations, investments or shareholder returns without refinancing pressure. This stability supports long-term strategic options and resilience in downturns.
Flagship brand strength
A well-recognized flagship product and established OTC distribution give durable demand and consumer loyalty. Brand-led sales through pharmacies and retail channels support steady revenues and pricing power over time, helping the company withstand competitive retail cycles.
Healthy gross margins
Sustained gross margins indicate core product profitability and manufacturing efficiency, which cushions operating profits from input cost swings. If management controls operating expenses, healthy gross margins support margin recovery and long-term earnings stability.
Negative Factors
Weakened profitability
A meaningful drop in net margin signals reduced earnings quality and less room to absorb shocks. Persistently lower margins constrain retained earnings for reinvestment, reduce return on capital, and may hamper the company's ability to deliver consistent shareholder returns over the medium term.
Negative free cash flow
Sharp deterioration in cash generation and poor cash conversion undermine financial flexibility despite low reported debt. Negative FCF limits capacity to fund investments or dividends internally, may force external financing, and raises risk that working-capital or capex trends are structural rather than temporary.
Low returns on equity
Modest ROE indicates the company struggles to convert its sizable equity base into strong profits. Over the medium term, low capital efficiency can limit growth prospects and investor returns unless margins or asset utilization improve materially.

Yomeishu Seizo Co., Ltd. (2540) vs. iShares MSCI Japan ETF (EWJ)

Yomeishu Seizo Co., Ltd. Business Overview & Revenue Model

Company DescriptionYomeishu Seizo Co., Ltd. produces and sells herbal liqueurs and pharmaceutical products in Japan, Hong Kong, Malaysia, Singapore, and Taiwan. It offers Yomeishu, an herbal liqueur; ginger, ginseng, honey, and medicinal liqueur; fruit and herbs liqueur; Kanomori and Kanoshizuku gin; and craft gin cocktail products. The company also provides Yomeishu cough drops; Yomeishu Seizo Amazake; Herb-no-Megumi; Ururu vinegar drinks; ginger black vinegar drinks; and dilution type black vinegar drinks. In addition, it offers Koken Seisai designated quasi-pharmaceutical and health products through the mail order site www.yomeishu-online.jp. Further, the company operates CLASUWA, a commercial complex; rents/leases real estate properties; manages restaurants and shops; and generates, supplies, and sells electricity through natural energy. Yomeishu Seizo Co., Ltd. was incorporated in 1923 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyYomeishu Seizo Co., Ltd. generates revenue primarily through the sale of its health-focused beverages, with the Yomeishu tonic being its flagship product. The company markets its products through various retail channels, including supermarkets, pharmacies, and online platforms, both domestically and internationally. Additionally, Yomeishu Seizo may engage in strategic partnerships and collaborations with other companies to expand its market reach and product offerings. The company's earnings are significantly influenced by consumer demand for health and wellness products, as well as its ability to innovate and introduce new products that meet consumer preferences.

Yomeishu Seizo Co., Ltd. Financial Statement Overview

Summary
Balance sheet strength is a major positive (zero debt and strong equity base), but overall fundamentals are dragged down by weakening profitability in 2025 (lower net and operating margins) and a sharp deterioration in cash generation, with operating cash flow falling and free cash flow turning deeply negative in 2024–2025.
Income Statement
64
Positive
Revenue has been broadly stable over the last several years (including modest declines in 2024 and a rebound in 2025), but profitability has weakened meaningfully: net margin fell from roughly 9–10% (2022–2024) to ~6.8% in 2025, and operating profit also stepped down sharply versus 2022–2024 levels. Gross margin remains healthy, but the 2025 drop indicates increased cost pressure and/or higher operating expenses, reducing earnings quality and consistency.
Balance Sheet
88
Very Positive
The balance sheet is very conservative with zero debt across all reported periods and a large equity base relative to assets, indicating strong financial flexibility and low insolvency risk. Returns on equity are positive but modest (roughly ~1.5% to ~2.4%), suggesting solid stability but limited efficiency in turning capital into profits—especially in 2025 as profitability softened.
Cash Flow
41
Neutral
Cash generation has become a key concern: operating cash flow declined materially in 2024–2025 versus 2022–2023, and free cash flow swung from strongly positive in 2022–2023 to deeply negative in 2024–2025. In 2025, operating cash flow covered only a small portion of net income (about 0.38x), pointing to weaker cash conversion, while the large negative free cash flow suggests heavy investment and/or working-capital headwinds that may persist if not temporary.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue9.99B10.02B10.24B10.65B10.58B10.38B
Gross Profit5.63B5.42B6.14B6.60B6.68B6.39B
EBITDA2.13B1.70B1.97B2.01B1.97B1.68B
Net Income784.26M679.58M952.82M1.02B949.90M807.56M
Balance Sheet
Total Assets52.55B53.52B54.42B49.56B48.61B47.87B
Cash, Cash Equivalents and Short-Term Investments5.05B5.71B8.15B8.93B5.89B9.14B
Total Debt0.000.000.000.000.000.00
Total Liabilities6.92B7.46B7.77B6.77B6.43B6.31B
Stockholders Equity45.63B46.06B46.64B42.79B42.18B41.56B
Cash Flow
Free Cash Flow0.00-2.67B-1.92B1.36B1.29B752.61M
Operating Cash Flow0.00473.12M667.52M1.75B1.81B1.41B
Investing Cash Flow0.00-1.19B2.31B-1.45B-1.40B-217.20M
Financing Cash Flow0.00-623.03M-760.15M-554.77M-551.81M-551.50M

Yomeishu Seizo Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4800.00
Price Trends
50DMA
4491.70
Negative
100DMA
4425.80
Negative
200DMA
3944.14
Positive
Market Momentum
MACD
-65.57
Positive
RSI
33.87
Neutral
STOCH
0.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2540, the sentiment is Negative. The current price of 4800 is above the 20-day moving average (MA) of 4388.75, above the 50-day MA of 4491.70, and above the 200-day MA of 3944.14, indicating a neutral trend. The MACD of -65.57 indicates Positive momentum. The RSI at 33.87 is Neutral, neither overbought nor oversold. The STOCH value of 0.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2540.

Yomeishu Seizo Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
¥70.35B9.733.63%1.78%19.50%
65
Neutral
¥62.22B17.760.65%17.33%12.37%
64
Neutral
¥12.75B8.483.94%11.47%29.21%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
52
Neutral
¥55.79B75.310.95%-0.50%-18.80%
51
Neutral
¥84.07B-27.571.01%6.00%-139.78%
48
Neutral
¥52.50B-63.893.68%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2540
Yomeishu Seizo Co., Ltd.
4,045.00
1,464.40
56.75%
JP:2585
LIFEDRINK COMPANY INC.
1,189.00
-432.69
-26.68%
JP:2590
DyDo Group Holdings, Inc.
2,610.00
-381.29
-12.75%
JP:2927
AFC-HD AMS Life Science Co., Ltd.
900.00
99.06
12.37%
JP:2931
euglena Co., Ltd.
377.00
-112.00
-22.90%
JP:4526
Riken Vitamin Co., Ltd.
3,085.00
805.50
35.34%

Yomeishu Seizo Co., Ltd. Corporate Events

Yomeishu Seizo Backs Tender Offer in Move Toward Privatization
Feb 25, 2026

Yomeishu Seizo’s board has endorsed a tender offer for its common shares by Reno Co., Ltd., while leaving individual shareholders free to decide whether to tender. The transaction is intended to take the company private and ultimately delist its shares from the Tokyo Stock Exchange.

The offer, priced at 4,050 yen per share, forms part of a multi-step restructuring that will result in Tsumura becoming Yomeishu’s sole shareholder after a series of post-offer procedures. The largest shareholder, Yuzawa Co., Ltd., has agreed not to tender its stake but will support squeeze-out measures, signaling a coordinated move toward consolidation and ownership realignment.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Reno Launches Tender Offer for Yomeishu Seizo Shares at ¥4,050
Feb 25, 2026

Reno, Inc. has launched a tender offer to acquire common shares of Yomeishu Seizo Co., Ltd., aiming to purchase up to 9,282,257 shares at 4,050 yen per share. The offer period runs from February 25 to April 8, 2026, with settlement scheduled to begin on April 15, positioning Reno to potentially obtain significant influence or control over the TSE Prime-listed health beverage maker.

The tender offer could reshape Yomeishu Seizo’s shareholder structure and strategic direction, with implications for its governance and long-term positioning in Japan’s health-oriented beverages market. Existing shareholders are presented with an exit opportunity at a defined premium price, while the outcome may signal further consolidation or strategic investment activity within the sector.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu Seizo Flags Heavy Extraordinary Losses, Scraps Dividend as It Backs Takeover and Delisting
Feb 24, 2026

Yomeishu Seizo has warned it will book significant extraordinary losses for the fiscal year ending March 31, 2026, driven by about ¥380 million in tender offer-related advisory and legal costs and a ¥2.93 billion impairment on underperforming CLASUWA-related assets. As a result, the company has sharply revised its non-consolidated net income forecast from a ¥840 million profit to a ¥1.64 billion loss, and decided to cut its year-end dividend for fiscal 2026 to zero, terminate its shareholder benefit program from fiscal 2027, and abandon its mid-term management plan, moves that underscore a major strategic reset as it supports a tender offer that is expected to lead to delisting and a shift to a single controlling shareholder.

The board has expressed support for the tender offer by Reno Co., Ltd., which aims to reduce Yomeishu’s shareholder base to a single stakeholder, TSUMURA & CO., implying a transition away from the public market and potentially reshaping governance and capital policy. These changes signal heightened short-term financial pressure and the end of existing shareholder return frameworks, with material implications for minority investors as the company reorients its strategy under an anticipated new ownership structure.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu Seizo to Book ¥485 Million Extraordinary Gain From Sale of Unlisted Security
Feb 24, 2026

Yomeishu Seizo Co., Ltd. has resolved at a recent board meeting to sell one unlisted investment security at the request of the investee company. The transaction, scheduled for April 2026, is expected to generate a gain on sale of 485 million yen, which will be recognized as extraordinary income.

The gain will be booked in the three months ending June 30, 2026, and will impact results for the fiscal year ending March 31, 2027. This one-off profit bolsters Yomeishu Seizo’s earnings profile and may temporarily enhance its financial position, although it does not reflect changes in its core beverage and health-products operations.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu to Exit Hisamitsu Stake, Books ¥413 Million Extraordinary Gain
Feb 10, 2026

Yomeishu Seizo Co., Ltd. has resolved to participate in a tender offer launched by Taiyo Kosan Co., Inc. for all 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. that it currently holds as strategic equity, citing the offer’s reasonable pricing and the Hisamitsu board’s support as factors that enhance its own corporate value. The shares will be tendered at 6,082 yen per share, for expected proceeds of about 614 million yen and an extraordinary gain of 413 million yen in the fiscal year ending March 31, 2026, though the company says its earnings forecast remains unchanged because gains from selling strategically held shares were already factored into its guidance.

The tender offer runs from January 7 to February 19, 2026, with settlement scheduled to begin on February 27, 2026, after which Yomeishu will hold no Hisamitsu shares. The move underscores a continued shift away from cross-shareholdings in Japan and signals Yomeishu’s efforts to optimize its portfolio and improve capital efficiency, while giving investors clearer visibility on the treatment of one-off gains in its current fiscal-year outlook.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu Seizo Denies Media Report on Buyout Details, Confirms Privatization Talks Ongoing
Feb 3, 2026

Yomeishu Seizo has clarified that recent Nikkei reports suggesting the company is considering going private, divesting certain businesses including its core Yomeishu business, and potentially involving Tsumura & Co. as a buyer are not based on any official company announcement. The company reiterated that, as previously disclosed, it is in discussions with its largest shareholder, Yuzawa, about specific methods for privatization and possible divestiture of some operations, but emphasized that no decisions have been made on transaction terms or prospective buyers, and pledged to promptly disclose any material decisions, underscoring ongoing strategic uncertainty for shareholders and business partners.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu Seizo Delivers Profit Growth Despite Lower Sales and Confirms Dividend Plan
Jan 29, 2026

For the nine months ended December 31, 2025, Yomeishu Seizo reported non-consolidated net sales of ¥7.33 billion, down 5.2% year on year, but achieved sharp profit recovery, with operating profit up 28.5% to ¥128 million, ordinary profit up 27.3% to ¥728 million, and net profit up 15.0% to ¥488 million, lifting basic earnings per share to ¥35.22. The company’s financial position remains strong, with total assets of ¥57.72 billion, equity of ¥48.88 billion and an equity ratio of 84.7%, and it is maintaining its previously announced full-year forecast for FY2025/26, including net sales of ¥9.63 billion, profit growth and an annual dividend of ¥45 per share, signaling continued commitment to shareholder returns despite modest top-line decline.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen4449.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu Ends Exclusive Talks With KKR, Shifts Privatization Focus to Largest Shareholder Yuzawa
Jan 4, 2026

Yomeishu Seizo has ended exclusive privatization talks with U.S. private equity fund KKR after concluding that KKR’s tender offer proposals were unlikely to be completed due to the firm stance of its largest shareholder, Yuzawa KK, which supports privatization but refuses to sell its stake. KKR’s initial and revised offers, centered on an indicated equity value of ¥4,021 per share and a tender offer structure dependent on Yuzawa’s participation, were rejected by Yuzawa, prompting Yomeishu to let KKR’s preferred negotiating rights lapse and effectively ruling out a KKR-led tender offer. The company, which has been running an “active market check” since mid‑2025 to explore value-enhancing options including going private, will now negotiate directly with Yuzawa on a Yuzawa-led privatization structure under which Yuzawa remains a shareholder, with an understood expectation that any transaction terms, including price per share, exceed those in the KKR proposal. Yomeishu also plans, in conjunction with Yuzawa, to consider transferring its businesses after privatization to a “best owner,” signaling potential future strategic realignment or asset transfers that could reshape the company’s ownership and operational structure for stakeholders.

The most recent analyst rating on (JP:2540) stock is a Hold with a Yen5064.00 price target. To see the full list of analyst forecasts on Yomeishu Seizo Co., Ltd. stock, see the JP:2540 Stock Forecast page.

Yomeishu Seizo Denies Imminent Tender Offer Despite Exclusive Talks With KKR
Dec 30, 2025

Yomeishu Seizo has clarified that a recent Bloomberg report suggesting the company is set to be privatized via a tender offer as early as January 2026 is not based on any official company announcement. While the company acknowledged that it has granted U.S. private equity firm KKR exclusive negotiation rights in a bidding process concerning a potential privatization, it emphasized that no decision has been made on launching a tender offer and that there is currently no prospect of such an offer occurring in January 2026. Yomeishu stated that any material decisions requiring disclosure will be announced promptly, signaling that discussions remain exploratory and that key terms and timing of any potential transaction are still uncertain for shareholders and other stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 26, 2026